Ropes and Gray: OBI Pharma Enters Licensing Agreement With Novartis for Next-Generation Antibody-Drug Conjugates Worth Over $2 Billion
November 18, 2026
November 18, 2026
BOSTON, Massachusetts, Nov. 18 -- Ropes and Gray, a law firm, posted the following news:
* * *
OBI Pharma Enters Licensing Agreement with Novartis for Next-Generation Antibody-Drug Conjugates Worth Over $2 Billion
November 17, 2026
Ropes & Gray advised Taiwan-based OBI Pharma in a collaboration and license agreement with Novartis Pharma AG in a transaction worth over $2 billion announced on November 13.
Under the agreement, Nov . . .
* * *
OBI Pharma Enters Licensing Agreement with Novartis for Next-Generation Antibody-Drug Conjugates Worth Over $2 Billion
November 17, 2026
Ropes & Gray advised Taiwan-based OBI Pharma in a collaboration and license agreement with Novartis Pharma AG in a transaction worth over $2 billion announced on November 13.
Under the agreement, Nov . . .
